# Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

> **NCT01220518** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 257 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT01220518
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-11
- **Final completion:** 2012-06
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2013-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220518, "Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01220518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*